Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136766 | 0.84 | CA2 (0.43) | PTGS1PTGS2CA1CA2LMNA | |
| SCHEMBL723478 | 0.81 | CA2 (0.40) | PTGS1PTGS2CA1CA2CYP1A2 | |
| SCHEMBL10136751 | 0.81 | CA2 (0.40) | PTGS1PTGS2CA1CA2CYP1A2 | |
| SCHEMBL18060590 | 0.80 | CA1 (0.36) | PTGS1PTGS2CA1CA2CNR2 | |
| SCHEMBL16583628 | 0.80 | MEN1 (0.34) | PTGS1PTGS2MEN1KMT2A | |
| SCHEMBL724696 | 0.78 | NR5A2 (0.39) | PTGS1PTGS2CA1CA2LMNA | |
| SCHEMBL18060588 | 0.71 | CA2 (0.37) | PTGS1PTGS2CA1CA2CYP1A2 | |
| SCHEMBL723503 | 0.71 | HPGD (0.38) | PTGS1PTGS2CA1CA2LMNA | |
| SCHEMBL27969314 | 0.71 | HPGD (0.38) | PTGS1PTGS2CA1CA2LMNA | |
| SCHEMBL18060596 | 0.68 | PTGS1 (0.36) | PTGS1PTGS2CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751084-B1 | PYRIMIDINE CARBOXAMIDE DERIVATIVES | EUDIS BIOTECH LLC (CN) | 2016-09-21 | — | — | EP | claimed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | claimed |
| US-8580805-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2013-11-12 | — | — | US | claimed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | claimed |
| US-9249107-B2 | Pyrimidine carboxamide derivatives | MAEHR HUBERT (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | Maehr, Hubert (US) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | NOD1, IL1B, IRAK1 | PTGS1 22/4885PTGS2 155/4885CA1 2949/4885 |
| US-20150087665-A1 | Pyrimidine carboxamide derivatives | NOD1, IL1B, IRAK1 | PTGS1 22/4885PTGS2 155/4885CA1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.